Johnson & Johnson(JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Latest News & Analysis
Johnson & Johnson: Nipocalimab, DARZALEX®, and Economic Outlook
JNJ navigates innovation, economic challenges, and strategic dividend decisions. Nipocalimab's potential in gMG and DARZALEX®'s impact on multiple myeloma are key.
Johnson & Johnson (JNJ): TREMFYA®, Acquisitions, and Market Analysis
Analysis of Johnson & Johnson (JNJ): TREMFYA® efficacy, Intra-Cellular Therapies acquisition, market resilience, and talc litigation impacts on JNJ stock.
Johnson & Johnson (JNJ): Litigation, Acquisitions, and Investor Outlook
Johnson & Johnson (JNJ) navigates talc litigation setbacks and expands into neuropsychiatry with the Intra-Cellular Therapies acquisition. A look at valuation and investor outlook.
Johnson & Johnson (JNJ): Innovation, Market Impact, and Future Outlook
Johnson & Johnson (JNJ) is navigating a dynamic market. Breakthroughs in oncology and neurology, plus U.S. investments, position JNJ for growth.
Johnson & Johnson: $55B Investment, Tremfya Approval, and Dividend King Status
Analysis of Johnson & Johnson's $55B U.S. investment, Tremfya's FDA approval for Crohn's, and its Dividend King status. Growth strategy & market impact insights.
Johnson & Johnson (JNJ): FDA Approval, US Investment & Market Impact
JNJ is making headlines with Tremfya's FDA approval for Crohn's, a $55B U.S. investment, and oncology advancements. A dividend aristocrat offering stability.
Johnson & Johnson (JNJ): Nipocalimab, Lawsuits, and Dividend Outlook
Johnson & Johnson (JNJ) faces a mix of promising drug developments, legal challenges, and dividend sustainability concerns. Nipocalimab's FDA Fast Track contrasts with Stelara biosimilar risks.
Johnson & Johnson (JNJ): Innovation, Legal Challenges & Market
Comprehensive analysis of Johnson & Johnson (JNJ) examining Icotrokinra's clinical trial results, Kenvue spin-off, ChemImage lawsuit, R&D spending, and defensive stock characteristics.
Johnson & Johnson (JNJ) Analysis: Pipeline, Dividends, Volatility
Analysis of Johnson & Johnson's pipeline shifts, Icotrokinra's potential, Aticaprant's setback, and dividend stability amidst market volatility.
Johnson & Johnson (JNJ): Icotrokinra's Promise, Setbacks, and Resilience
JNJ navigates a dynamic healthcare landscape with Icotrokinra's promise, Aticaprant's setback, and strategic acquisitions, influencing market resilience.
Johnson & Johnson (JNJ): MedTech Expansion Offsets R&D Setbacks in 2025
Johnson & Johnson faces mixed outlook in 2025. R&D setbacks offset by MedTech growth. Dividend Aristocrat status provides stability amid market volatility.
Johnson & Johnson (JNJ): Strategic Shifts, Dividends, and Market Outlook
An intraday snapshot on March 5, 2025 detailing JNJ’s leadership transitions, dividend strategy, and innovative product launches.
Johnson & Johnson (JNJ): Navigating Market Trends
Johnson & Johnson (JNJ) navigates biosimilar competition, strategic acquisitions, and market trends, impacting investors. Stay informed with our in-depth analysis.
Johnson & Johnson (JNJ): Navigating Biosimilars, Acquisitions, and Market Trends
Johnson & Johnson (JNJ) navigates biosimilar competition, strategic acquisitions, and legal challenges in a dynamic healthcare market. Analysis and key insights provided.
Johnson & Johnson (JNJ): Navigating Biosimilars, Legal Battles, and Innovation
Johnson & Johnson navigates biosimilar competition, legal battles, and pharmaceutical innovations, impacting its market position and financial health.
Johnson & Johnson: Developments, Market Impact, and Industry Trends
Analysis of Johnson & Johnson's developments, market impact, and industry trends. Explore the baby powder settlement, biosimilar competition, and TREMFYA's potential.
J&J Under Pressure: Stelara Biosimilar Arrives as TREMFYA Shows Promise
Johnson & Johnson navigates biosimilar competition, promising TREMFYA data, and legal challenges amid a dynamic healthcare landscape.
Johnson & Johnson: Key Developments, Market Impact, and Industry Trends
Johnson & Johnson navigates legal battles, innovation, and market shifts. Key developments include baby powder litigation and Varipulse rollout. Stay informed.
Johnson & Johnson: Baby Powder Settlement, Pipeline Updates, and Market Impact
A detailed update on JNJ’s legal battles, pipeline shifts, and market performance as the company navigates key challenges.
Johnson & Johnson’s $10 Billion Baby Powder Battle: Will It Endure?
An in‐depth update on [JNJ](/dashboard/companies/JNJ)’s legal challenges, pipeline developments and strategic initiatives, with actionable insights for investors.